Coherus BioSciences (NASDAQ:CHRS) Stock, Quote.Headers.trade-ideas

Coherus BioSciences

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ACRS

AFRM

AGFY

BFRG

CHPT

CHRS

CISS

CLDI

COMM

CXAI

DWAC

FRES

FSLY

FTEL

GILD

Intelligent Bio Solutions Inc. - Common Stock

INBS

Airspan Networks Holdings Inc. Common Stock

MIMO

NEXI

NVVE

OCTO

PCSA

RILY

RVSN

SAVE

SGMT

STNE

TAOP

TNYA

UPST

VIRI

WISA

Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session.

B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the price target from $2.1 to $2.

CommScope shares dipped 6.9% to $2.2150 on Monday.

Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

cancer

Biotech

Equities

Health Care

Asset Sales

General

SDZNY

SDZXF

Coherus BioSciences agreed to sell its ophthalmology franchise for $170M to Sandoz. This aligns with CHRS&#39; focus on oncology and will help reduce debt and overhead costs.

Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today?

Pre-Market Outlook

ASTL

CELU

GBNH

HNRA

HUBC

MARK

Nuveen Insured California Premium Fund Ii

PRCH

TCBP

UNCY

Shares of  Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose sharply in today’s pre-market trading after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million upfront all cash deal.

Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket

Coherus BioSciences Inc

Baird analyst Colleen Kusy maintains Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Outperform and lowers the price target from $9 to $8.

Price Target

Analyst Ratings

Baird Maintains Outperform on Coherus BioSciences, Lowers Price Target to $8

Coherus BioSciences To Divest YUSIMRY In $40M Upfront All Cash Transaction

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Buy and maintains $12 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $12 Price Target

Truist Securities analyst Robyn Karnauskas maintains Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Buy and lowers the price target from $8 to $7.

Truist Securities Maintains Buy on Coherus BioSciences, Lowers Price Target to $7

HC Wainwright &amp; Co. analyst Douglas Tsao maintains Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Buy and raises the price target from $11 to $12.

HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Raises Price Target to $12

WIIM

Coherus BioSciences shares are trading lower after the company reported better-than-expected Q1 financial results.

Earnings

Earnings Misses

Coherus BioSciences Q1 2024 Adj EPS $(0.32) Misses $(0.24) Estimate, Sales $77.063M Miss $80.248M Estimate

<ul>
<li>New $38.7 million term loan with a May 2029 maturity</li>
<li>$37.5 million royalty monetization financing based on future sales of LOQTORZI&nbsp;and UDENYCA</li>
</ul>

Coherus Announces Full Repayment of Pharmakon Advisors $75M Term Loan

Contracts

Coherus To Collaborate With Cancer Research Institute On Novel Combination Evaluating LOQTORZI With ENB Therapeutics' ENB-003 For Treatment Of Ovarian Cancer

– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion – – Mechanism may enhance antitumor responses with immunotherapy – – First novel immuno-oncology product candidate discovered and developed by Coherus – – The CHS-1000 IND submission is planned for Q2 2024 –
REDWOOD CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus, NASDAQ:<a href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>), today presented preclinical data for its immuno-oncology pipeline candidate, CHS-1000, a novel ILT4 monoclonal antibody, at the 2024 AACR Annual Meeting being held in San Diego, California. Data presented show CHS-1000 is a potent monoclonal antibody that binds selectively to human ILT4 (also known as LILRB2) with high affinity, efficiently blocking interaction with its ligands and reversing immunosuppressive functions, leading to activation of human dendritic cells and T cells and promoting polarization of macrophages to an inflammatory M1 phenotype.
"Myeloid cell-mediated immunosuppression in the tumor microenvironment is a major contributor to tumor immune invasion and PD-1 resistance. The data presented in this poster demonstrate the potential for CHS-1000 to reverse myeloid suppression and activate an inflammatory immune response. Reprogramming myeloid cells in the tumor microenvironment holds promise as a new immuno-therapy approach with the aim to overcome resistance to I-O therapy and potentially provide benefit to more cancer patients," said Theresa LaVallee, Ph.D., Chief Development Officer at Coherus. "CHS-1000 is our first internally discovered development candidate, and we are excited to be filing the IND this quarter. We plan to advance CHS-1000 into the clinic both as a single agent and in combination with LOQTORZI&#xAE;."
These data will be presented today in a poster session, and the poster will be available for download at the time of the presentation:
Abstract: 1364/15 Title: <a href="https://www.globenewswire.com/Tracker?data=b-uQ9Bkof9Sji0aB982AtyOYvcv5Xl-9Bg9u2FJd0Z1liW4GB5t0Qgq2Ep1KWsfekasaWY-N33KqwYrlBZtQxusWWKPTiS-GA0mwE7o2RvwYkQg0uXBMa9gl8RdlqFqrV0THxMh1zr2rspAeYvllpvOG6lwLFIVSKQqQWd4DGjecPUH8-DUNb2WvexstyaFmngapN03lg6fyasDGuts65XpKVosuEY8LcQlbErxzHf8tVk_AeFQzQy_1mf9ijcO8Rf11betnAxEADYdPYqkyl5D_0CrjbVV2XycAXZ-ifLk=">Characterization of CHS-1000, an Fc-modified anti-ILT4 monoclonal antibody for reprogramming suppressive myeloid cells in solid tumors</a> Presenting author: Narendiran Rajasekaran, Ph.D. Session PO.IM01.02 – Immune Checkpoints and Inhibitory Molecules 1 Date and Time: Monday, April 8, 2024, 9:00 a.m. – 12:30 p.m. Pacific Daylight Time
Poster data are summarized as follows:
<ul>
<li>CHS-1000 binds specifically and selectively to human ILT4 (LILRB2) with high affinity and showed no cross-reactivity to other LILRB family members.</li>
<li>CHS-1000 efficiently blocks the interaction of ILT4 with its ligands, HLA-A and HLA-G, and reverses ILT4-mediated immunosuppressive functions, leading to activation of M1 macrophages, dendritic cells, and T cells and increases in pro-inflammatory cytokine secretion in in vitro assays.</li>
<li>CHS-1000 is Fc silent and lacks effector function activity in in vitro assays consistent with the engineered modification of the Fc region of the antibody. It also has IgG1‑like PK parameters in human FcRn transgenic mice.
<ul>
<li>ILT4 and CD163, a marker of suppressive (M2) macrophages, are highly expressed in a broad range of solid tumors.</li>
</ul>
</li>
</ul>

Coherus Presents Preclinical Data For CHS-1000, A Novel Anti-ILT4 Antibody, At The 2024 AACR Annual Meeting

HC Wainwright &amp; Co. analyst Douglas Tsao maintains Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Buy and lowers the price target from $13 to $11.

HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Lowers Price Target to $11

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Buy and maintains $13 price target.

HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $13 Price Target

Coherus BioSciences shares are trading lower after the company reported worse-than-expected Q4 financial results.

Guidance

Coherus BioSciences Sees FY24 R&D And SG&A Expenses $250M-$265M

Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) reported its Q4 earnings results on Wednesday, March 13, 2024 at 04:01 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Coherus BioSciences missed estimated earnings by -417.0%, reporting an EPS of $-0.62 versus an estimate of $-0.12.
Revenue was up $46.17 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.04 which was followed by a 30.0% drop in the share price the next day.
Here's a look at Coherus BioSciences's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.31</td>
<td>-0.52</td>
<td>-0.57</td>
<td>-0.84</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.27</td>
<td>-0.38</td>
<td>-0.75</td>
<td>-0.60</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>83.56M</td>
<td>50.83M</td>
<td>47.44M</td>
<td>51.22M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>74.57M</td>
<td>58.72M</td>
<td>32.44M</td>
<td>45.35M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Coherus BioSciences <a href="https://www.benzinga.com/quote/CHRS/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Coherus BioSciences Q4 Earnings

Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.12) by 416.67 percent. The company reported quarterly sales of $91.524 million which missed the analyst consensus estimate of $96.400 million by 5.06 percent. This is a 101.81 percent increase over sales of $45.352 million the same period last year.

Coherus BioSciences Q4 2023 Adj EPS $(0.62) Misses $(0.12) Estimate, Sales $91.524M Miss $96.400M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.
&bull; Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) is expected to report earnings for its fourth quarter.
&bull; Optical Cable (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCC#NASDAQ">OCC</a>) is likely to report earnings for its first quarter.
&bull; Perma-Fix Envirn Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PESI#NASDAQ">PESI</a>) is likely to report quarterly earnings at $0.06 per share on revenue of $22.50 million.
&bull; Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) is estimated to report quarterly earnings at $2.65 per share on revenue of $8.67 billion.
&bull; Magic Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGIC#NASDAQ">MGIC</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $117.50 million.
&bull; Petco Health and Wellness (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $1.62 billion.
&bull; iShares $ Corp Bond UCITS ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) is estimated to report quarterly loss at $0.23 per share on revenue of $4.73 million.
&bull; Aadi Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AADI#NASDAQ">AADI</a>) is estimated to report quarterly loss at $0.65 per share on revenue of $6.29 million.
&bull; Moolec Science (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLEC#NASDAQ">MLEC</a>) is likely to report quarterly loss at $0.07 per share on revenue of $600 thousand.
&bull; ADC Therapeutics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>) is likely to report quarterly loss at $0.50 per share on revenue of $15.33 million.
&bull; Target Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TH#NASDAQ">TH</a>) is expected to report quarterly earnings at $0.24 per share on revenue of $118.00 million.
&bull; iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) is expected to report quarterly loss at $0.24 per share on revenue of $3.04 million.
&bull; WideOpenWest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOW#NYSE">WOW</a>) is projected to report quarterly loss at $0.01 per share on revenue of $170.57 million.
&bull; Tuniu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOUR#NASDAQ">TOUR</a>) is estimated to report earnings for its fourth quarter.
&bull; Arcos Dorados Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARCO#NYSE">ARCO</a>) is expected to report quarterly earnings at $0.31 per share on revenue of $1.15 billion.
&bull; ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) is estimated to report quarterly loss at $1.29 per share on revenue of $1.28 billion.
&bull; ProFrac Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACDC#NASDAQ">ACDC</a>) is projected to report quarterly earnings at $0.02 per share on revenue of $594.97 million.
&bull; Sharecare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHCR#NASDAQ">SHCR</a>) is likely to report quarterly loss at $0.06 per share on revenue of $114.99 million.
&bull; Village Farms Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) is likely to report quarterly loss at $0.02 per share on revenue of $69.79 million.
&bull; Vera Bradley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) is likely to report quarterly earnings at $0.14 per share on revenue of $136.05 million.
&bull; Global Indemnity Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBLI#NYSE">GBLI</a>) is likely to report quarterly earnings at $0.54 per share on revenue of $141.00 million.
<h3>Companies Reporting After The Bell</h3>
&bull; i-80 Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IAUX#AMEX">IAUX</a>) is estimated to report earnings for its fourth quarter.
&bull; RCM Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCMT#NASDAQ">RCMT</a>) is expected to report quarterly earnings at $0.62 per share on revenue of $72.29 million.
&bull; Adams Resources &amp; Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AE#AMEX">AE</a>) is projected to report quarterly loss at $0.08 per share on revenue of $678.36 million.
&bull; Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) is projected to report quarterly loss at $0.12 per share on revenue of $96.40 million.
&bull; Profire Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFIE#NASDAQ">PFIE</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $14.61 million.
&bull; Jowell Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JWEL#NASDAQ">JWEL</a>) is projected to report quarterly earnings at $0.73 per share on revenue of $228.53 million.
&bull; MorphoSys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOR#NASDAQ">MOR</a>) is estimated to report quarterly earnings at $0.09 per share on revenue of $67.89 million.
&bull; North American (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOA#NYSE">NOA</a>) is likely to report quarterly earnings at $0.74 per share on revenue of $248.81 million.
&bull; Pangaea Logistics Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANL#NASDAQ">PANL</a>) is expected to report quarterly earnings at $0.34 per share on revenue of $140.16 million.
&bull; Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) is likely to report earnings for its fourth quarter.
&bull; VAALCO Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EGY#NYSE">EGY</a>) is estimated to report quarterly earnings at $0.12 per share on revenue of $129.06 million.
&bull; SuRo Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSSS#NASDAQ">SSSS</a>) is projected to report quarterly loss at $0.14 per share on revenue of $1.10 million.
&bull; scPharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCPH#NASDAQ">SCPH</a>) is projected to report quarterly loss at $0.42 per share on revenue of $5.52 million.
&bull; NextNav (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NN#NASDAQ">NN</a>) is estimated to report quarterly loss at $0.14 per share on revenue of $1.19 million.
&bull; Hallador Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNRG#NASDAQ">HNRG</a>) is projected to report quarterly earnings at $0.29 per share on revenue of $199.20 million.
&bull; Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) is projected to report quarterly loss at $0.10 per share on revenue of $18.63 million.
&bull; Fossil Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOSL#NASDAQ">FOSL</a>) is likely to report earnings for its fourth quarter.
&bull; electroCore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECOR#NASDAQ">ECOR</a>) is likely to report quarterly loss at $0.61 per share on revenue of $4.97 million.
&bull; OPAL Fuels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPAL#NASDAQ">OPAL</a>) is estimated to report quarterly earnings at $0.17 per share on revenue of $88.52 million.
&bull; Limbach Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMB#NASDAQ">LMB</a>) is estimated to report quarterly earnings at $0.40 per share on revenue of $129.37 million.
&bull; Lennar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) is estimated to report quarterly earnings at $2.20 per share on revenue of $7.39 billion.
&bull; Superior Gr of Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGC#NASDAQ">SGC</a>) is projected to report quarterly earnings at $0.15 per share on revenue of $142.86 million.
&bull; Turtle Beach (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEAR#NASDAQ">HEAR</a>) is estimated to report quarterly earnings at $0.60 per share on revenue of $111.60 million.
&bull; Cue Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLTH#NASDAQ">HLTH</a>) is likely to report quarterly loss at $0.44 per share on revenue of $17.68 million.
&bull; Navigator Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVGS#NYSE">NVGS</a>) is expected to report quarterly earnings at $0.30 per share on revenue of $130.76 million.
&bull; GrowGeneration (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) is likely to report quarterly loss at $0.13 per share on revenue of $45.52 million.
&bull; Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) is expected to report quarterly loss at $0.26 per share on revenue of $41.40 million.
&bull; FTC Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTCI#NASDAQ">FTCI</a>) is estimated to report quarterly loss at $0.07 per share on revenue of $23.12 million.
&bull; BGSF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGSF#NYSE">BGSF</a>) is estimated to report quarterly earnings at $0.08 per share on revenue of $75.05 million.
&bull; Boxlight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOXL#NASDAQ">BOXL</a>) is expected to report quarterly loss at $0.63 per share on revenue of $36.55 million.
&bull; SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) is projected to report quarterly loss at $0.04 per share on revenue of $169.53 million.
&bull; Gold Resource (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GORO#AMEX">GORO</a>) is projected to report quarterly loss at $0.09 per share on revenue of $18.95 million.
&bull; Logan Ridge Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRFC#NASDAQ">LRFC</a>) is likely to report quarterly earnings at $0.50 per share on revenue of $5.00 million.
&bull; KORU Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRMD#NASDAQ">KRMD</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $6.94 million.
&bull; Portman Ridge Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTMN#NASDAQ">PTMN</a>) is likely to report quarterly earnings at $0.79 per share on revenue of $19.04 million.
&bull; ESS Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) is likely to report quarterly loss at $0.11 per share on revenue of $3.54 million.
&bull; UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) is estimated to report quarterly earnings at $0.16 per share on revenue of $383.83 million.
&bull; Vroom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRM#NASDAQ">VRM</a>) is projected to report quarterly loss at $29.60 per share on revenue of $232.00 million.
&bull; Ocean Power Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#AMEX">OPTT</a>) is projected to report earnings for its third quarter.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

AADI

ACDC

ADCT

ANIK

ARCO

BGSF

BOXL

DLTR

ECOR

FOSL

FTCI

GBLI

GORO

GRWG

HEAR

HLTH

HNRG

IAUX

ISPC

JWEL

KRMD

LQDA

LRFC

MGIC

MLEC

Morgan Stanley Capital Protected Notes for S&P 500 Index

NVGS

OPAL

OPTT

PANL

PATH

PESI

PFIE

PTMN

QNRX

RCMT

SCPH

SGMO

SHCR

SPRO

SSSS

TOUR

WOOF

Earnings Scheduled For March 13, 2024

Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-03-13. Here's what investors need to know before the announcement.
Analysts estimate that Coherus BioSciences will report an earnings per share (EPS) of $-0.12. 
Coherus BioSciences bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.04, which was followed by a 30.23% drop in the share price the next day.
Here's a look at Coherus BioSciences's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.31</td>
<td>-0.52</td>
<td>-0.57</td>
<td>-0.84</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.27</td>
<td>-0.38</td>
<td>-0.75</td>
<td>-0.60</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-30.0%</td>
<td>18.0%</td>
<td>-27.0%</td>
<td>8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1710259238_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Coherus BioSciences were trading at $2.27 as of March 11. Over the last 52-week period, shares are down 63.34%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/CHRS/earnings">To track all earnings releases for Coherus BioSciences visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For Coherus BioSciences

– Innovative design enables five-minute pegfilgrastim-cbqv delivery time –
– Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving UDENYCA&#xAE; –

Coherus Launches UDENYCA ONBODY For Pegfilgrastim-cbqv

Baird analyst Colleen Kusy maintains Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Outperform and lowers the price target from $11 to $9.

Baird Maintains Outperform on Coherus BioSciences, Lowers Price Target to $9

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Johnson & Johnson (JNJ – Research Report), Eli Lil...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Johnson & Johnson (JNJ), Eli Lilly & Co (LLY) and Coherus Biosciences (CHRS)

Analyst Douglas Tsao of H.C. Wainwright reiterated a Buy rating on Coherus Biosciences (CHRS – Research Report), retaining the price target of $12....

Buy Rating Affirmed for Coherus Biosciences on CHS-114's Promising Clinical Data and Strong Financial Projections

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

Coherus Biosciences (CHRS) just unveiled an announcement. Coherus BioSciences, Inc. has expanded its Board of Directors and appointed Rita A. Karac...

Coherus Biosciences Appoints Rita Karachun to Board

FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

Pfizer: Seriously Undervalued At Peak Pessimism

Coherus to divest biosimilar against AbbVie's Humira for $40M

Shanghai Henlius Biotech agreed to be a wholly owned subsidiary of Fosun in a $690 million deal that values the company at $1.7 billion. Meanwhile, Suzhou Ascentage Pharma filed to list in the US to support its portfolio of drugs.

Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary

Coherus out licenses Canadian rights to cancer drug Loqtorzi

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Coherus Biosciences (CHRS – Research Report), with a price targe...

Barclays Reaffirms Their Buy Rating on Coherus Biosciences (CHRS)

ABBV

ASPHF

BMYMP

CASI

DSKYF

DSNKY

FGEN

IVBXF

REGN

SHJBF

TKPHF

Press Releases

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Coherus to Report First Quarter 2024 Financial Results on May 9, 2024

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

Financing

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

Management

Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Coherus BioSciences

Coherus BioSciences (CHRS) Forecast

Coherus BioSciences (NASDAQ:CHRS) Stock, Quote.Headers.trade-ideas